MedTrace Logo

The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca

NCT02250976 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-08-03

No results posted yet for this study

Summary

To evaluate the comparative pharmacokinetics and safety of fixed-dose combination versus coadministration of Lipilfen cap.160mg(micronized fenofibrate160mg) and Livalo tab. 2mg(pitavastatin Ca 2mg) under fed condition in healthy male volunteers.

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

Livasupril Cap.160/2mg

Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg

DRUG

Lipilfen cap. 160mg

Micronized fenofibrate 160mg

DRUG

Livaro tab. 2mg

Pitavastatin Ca 2mg

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Young-Ran Yoon, M.D., Ph.D. · Kyungpook National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02250976 on ClinicalTrials.gov